Get the Stockscreener App
6.52
0.31%
-0.02
After Hours:
6.86
0.34
+5.21%
Bioventus Inc stock is traded at $6.52, with a volume of 683.98K.
It is down -0.31% in the last 24 hours and down -1.51% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$6.54
Open:
$6.42
24h Volume:
683.98K
Relative Volume:
1.55
Market Cap:
$432.65M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-10.87
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
+1.87%
1M Performance:
-1.51%
6M Performance:
-38.95%
1Y Performance:
-6.99%
1-Day Range:
$6.41
$6.78
1-Week Range:
$6.33
$6.91
52-Week Range:
$6.02
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.52 | 433.98M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Competitive Positioning of Bioventus Inc.: Is It Leading or LaggingFree Low Risk High Return Opportunities - Newser
Should I hold or sell Bioventus Inc. stock in 2025Financial News Data Feed With High Returns - jammulinksnews.com
Bioventus gets FDA nod for pain management devices - MSN
Bioventus Gains FDA Clearance for Key PNS Products - TipRanks
Top chart patterns to watch in Bioventus Inc.Buy Alert Based on RSI and Volume - Newser
How volatile is Bioventus Inc. stock compared to the marketDaily Trading Tips That Work - jammulinksnews.com
Price action breakdown for Bioventus Inc.Yield Curve Outlook and Long-Term Implication Summary - Newser
Is it the right time to buy Bioventus Inc. stockBest Dividend Insights For Consistent Profits - jammulinksnews.com
What’s next for Bioventus Inc. stock priceAI Trend Detection for Entry Timing - Newser
Can Bioventus Inc. recover in the next quarterGrowth Watchlist for Long Term Positioning - Newser
How Bioventus Inc. stock performs during market volatilityCapital Growth With Controlled Risk Picks Suggested - beatles.ru
Bioventus receives FDA clearance for two pain management devices By Investing.com - Investing.com UK
Bioventus gets FDA nod for pain management devices (BVS) - Seeking Alpha
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products - The Manila Times
The FDA Grants 510(k) Clearances For Bioventus' Talismann And Stimtrial, Expanding The Company's Portfolio Of Peripheral Nerve Stimulation Solutions For Chronic Pain Management - 富途牛牛
Bioventus Secures Dual FDA Clearance for Revolutionary Non-Opioid Pain Management Technology - Stock Titan
What makes Bioventus Inc. stock price move sharplySector-Wise Stock Strength Trend Analysis - Newser
Momentum divergence signals in Bioventus Inc. chartFree Reliable Chart-Based Trade Entries - Newser
New Product Launches: Will They Boost Bioventus Inc. Stock in 2025Breakout Monitoring with Momentum Analysis - Newser
What indicators show strength in Bioventus Inc.Stock Entry Points Based on Technicals - Newser
Bioventus Inc. Recovery Gathers Momentum on Chart SignalsRisk Adjusted Technical Entry Plan Gains Followers - metal.it
What candlestick patterns are forming on Bioventus Inc.Free Swing Setup With Technical Confirmation - Newser
What to do if you’re stuck in Bioventus Inc.Free Conservative Entry for High Return Setup - Newser
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 - The Manila Times
Why Bioventus Inc. stock attracts strong analyst attentionReliable Alerts for Daily Stock Movers Released - metal.it
Regression Model Predicts Rangebound Movement in Bioventus Inc.AI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
What is the dividend policy of Bioventus Inc. stockInvest confidently with professional market insights - jammulinksnews.com
Does Bioventus Inc. stock perform well during market downturnsInvest confidently with professional guidance - jammulinksnews.com
Momentum divergence signals in Bioventus Inc. chart Market Correction Proof Stock Screening Analysis - Newser
Is Bioventus Inc. a growth stock or a value stockInvest smarter with cutting-edge analytics - jammulinksnews.com
What indicators show strength in Bioventus Inc. AI Intraday Market Movement Prediction Tool - Newser
What’s next for Bioventus Inc. stock price Buy Zone Strategy with Pattern Recognition - Newser
How does Bioventus Inc. compare to its industry peersAchieve breakthrough investment performance - jammulinksnews.com
How does Bioventus Inc. generate profit in a changing economyConsistent triple returns - jammulinksnews.com
What institutional investors are buying Bioventus Inc. stockFind market-beating stocks for your portfolio - jammulinksnews.com
Why is Bioventus Inc. stock attracting strong analyst attentionBuild wealth faster with expert stock selection - jammulinksnews.com
Is Bioventus Inc. Stock a Good Fit for Conservative InvestorsHigh Accuracy Alerts - Newser
Key External Factors That Drive Bioventus Inc. Stock Price MovementsFree Daily Stock Market Updates - Newser
What drives Bioventus Inc. stock priceFree Consultation - PrintWeekIndia
What analysts say about Bioventus Inc. stockConsistent wealth multiplication - PrintWeekIndia
Bioventus Inc. Stock Analysis and ForecastUnmatched market gains - PrintWeekIndia
Is Bioventus Inc. a good long term investmentMarket-crushing profits - PrintWeekIndia
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):